Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2013 | -14.42 Million USD | 84.56% |
| 2012 | -93.41 Million USD | -52.22% |
| 2011 | -61.36 Million USD | -336.0% |
| 2010 | -14.07 Million USD | 81.61% |
| 2009 | -76.53 Million USD | 11.54% |
| 2008 | -86.51 Million USD | -100.86% |
| 2007 | -43.06 Million USD | 10.81% |
| 2006 | -48.28 Million USD | -48.23% |
| 2005 | -32.57 Million USD | -52.24% |
| 2004 | -21.39 Million USD | 24.55% |
| 2003 | -28.36 Million USD | -1.12% |
| 2002 | -28.04 Million USD | -173.78% |
| 2001 | -10.24 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2014 Q1 | -1.39 Million USD | 2.73% |
| 2014 Q2 | 7.2 Million USD | 617.89% |
| 2013 Q2 | 15.37 Million USD | 157.63% |
| 2013 Q3 | -1.69 Million USD | -111.01% |
| 2013 Q4 | -1.43 Million USD | 15.43% |
| 2013 Q1 | -26.67 Million USD | 60.93% |
| 2013 FY | -14.42 Million USD | 84.56% |
| 2012 FY | -93.41 Million USD | -52.22% |
| 2012 Q4 | -68.27 Million USD | -177.1% |
| 2012 Q3 | -24.63 Million USD | 22.9% |
| 2012 Q2 | -31.95 Million USD | -201.6% |
| 2012 Q1 | 31.45 Million USD | 206.83% |
| 2011 Q4 | -29.44 Million USD | -199.93% |
| 2011 FY | -61.36 Million USD | -336.0% |
| 2011 Q2 | -12.51 Million USD | -30.53% |
| 2011 Q3 | -9.81 Million USD | 21.59% |
| 2011 Q1 | -9.59 Million USD | 16.53% |
| 2010 Q2 | 17.31 Million USD | 320.09% |
| 2010 FY | -14.07 Million USD | 81.61% |
| 2010 Q4 | -11.49 Million USD | 4.48% |
| 2010 Q3 | -12.03 Million USD | -169.49% |
| 2010 Q1 | -7.86 Million USD | 45.06% |
| 2009 Q2 | -22.09 Million USD | -1.62% |
| 2009 FY | -76.53 Million USD | 11.54% |
| 2009 Q4 | -14.31 Million USD | 22.11% |
| 2009 Q3 | -18.38 Million USD | 16.79% |
| 2009 Q1 | -21.74 Million USD | 15.75% |
| 2008 Q3 | -26.21 Million USD | -38.57% |
| 2008 Q2 | -18.91 Million USD | -21.4% |
| 2008 Q4 | -25.8 Million USD | 1.56% |
| 2008 FY | -86.51 Million USD | -100.86% |
| 2008 Q1 | -15.58 Million USD | -11.74% |
| 2007 Q4 | -13.94 Million USD | -9.74% |
| 2007 Q2 | -9.24 Million USD | -28.96% |
| 2007 Q1 | -7.17 Million USD | -72.26% |
| 2007 FY | -43.06 Million USD | 10.81% |
| 2007 Q3 | -12.7 Million USD | -37.39% |
| 2006 Q4 | -4.16 Million USD | -2.49% |
| 2006 Q3 | -4.06 Million USD | 86.42% |
| 2006 FY | -48.28 Million USD | -48.23% |
| 2006 Q2 | -29.91 Million USD | -194.86% |
| 2006 Q1 | -10.14 Million USD | 2.74% |
| 2005 Q3 | -7.38 Million USD | 0.0% |
| 2005 Q1 | -7.38 Million USD | -40.03% |
| 2005 Q4 | -10.43 Million USD | -41.34% |
| 2005 FY | -32.57 Million USD | -52.24% |
| 2005 Q2 | -7.38 Million USD | 0.0% |
| 2004 Q2 | -5.37 Million USD | 0.0% |
| 2004 Q1 | -5.37 Million USD | 0.0% |
| 2004 FY | -21.39 Million USD | 24.55% |
| 2004 Q4 | -5.27 Million USD | 1.95% |
| 2004 Q3 | -5.37 Million USD | 0.0% |
| 2003 FY | -28.36 Million USD | -1.12% |
| 2002 FY | -28.04 Million USD | -173.78% |
| 2001 FY | -10.24 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -980.101% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -106.564% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 127.226% |
| Nascent Biotech, Inc. | -2.08 Million USD | -590.91% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1314.118% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 122.145% |
| Qrons Inc. | -789.34 Thousand USD | -1727.333% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2180.81% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 76.958% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3371.656% |
| Skye Bioscience, Inc. | -37.64 Million USD | 61.684% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 80.759% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -119.339% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -5175.748% |
| SQZ Biotechnologies Company | -79.46 Million USD | 81.848% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -398.687% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -692.298% |
| Mesoblast Limited | -87.95 Million USD | 83.601% |
| Marizyme, Inc. | -65.34 Million USD | 77.927% |
| Genus plc | 7.9 Million USD | 282.582% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -32.431% |
| Pharming Group N.V. | -10.54 Million USD | -36.746% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -564.757% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -288.763% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -63.094% |
| ContraFect Corporation | -65.15 Million USD | 77.861% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -195.207% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -734.986% |
| IMV Inc. | -36.48 Million USD | 60.467% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -78.965% |
| MultiCell Technologies, Inc. | -380.07 USD | -3794990.378% |
| ONE Bio Corp. | 8.67 Million USD | 266.24% |
| Accustem Sciences Inc. | -3.74 Million USD | -285.008% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 72.096% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1038.317% |
| Q BioMed Inc. | -2.05 Million USD | -602.892% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -286.392% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -505.829% |
| Biomind Labs Inc. | -1.21 Million USD | -1087.826% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 75.849% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -365.025% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -82.511% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -639.977% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -96214.103% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 9.12% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -147.952% |
| GB Sciences, Inc. | -1.36 Million USD | -959.282% |
| Alpha Cognition Inc. | -13.77 Million USD | -4.73% |
| HST Global, Inc. | -146.21 Thousand USD | -9765.262% |
| CSL Limited | 2.64 Billion USD | 100.546% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -721.988% |
| Halberd Corporation | -79.67 Thousand USD | -18003.318% |
| Enzolytics Inc. | -2.17 Million USD | -562.614% |
| Agentix Corp. | -1.37 Million USD | -949.62% |
| Resverlogix Corp. | -3.61 Million USD | -299.557% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -354.81% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 95.111% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 14818.367% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 308.301% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -263.051% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -376.648% |
| AVAX Technologies, Inc. | -6.41 Million USD | -124.895% |
| Zenith Capital Corp. | -10.59 Million USD | -36.127% |
| Genscript Biotech Corporation | -95.47 Million USD | 84.893% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -61960.064% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -247.907% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -23764.749% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -619.36% |
| Kadimastem Ltd | -3.3 Million USD | -336.113% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1265.835% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -277.69% |
| BioStem Technologies, Inc. | -8.48 Million USD | -70.035% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3168.014% |
| LadRx Corporation | 400.44 Thousand USD | 3702.011% |
| Cell Source, Inc. | -5.32 Million USD | -171.066% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1509.271% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1509.271% |
| NovAccess Global Inc. | -4.76 Million USD | -202.441% |
| Itoco Inc. | -1.86 Million USD | -671.752% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -224.679% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -764.23% |
| Mobile Lads Corp. | -2.26 Million USD | -537.302% |
| CytoDyn Inc. | -49.84 Million USD | 71.06% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -18150.604% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -6222.794% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1431.976% |
| SYBLEU INC | -180.3 Thousand USD | -7899.823% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -794.38% |
| International Stem Cell Corporation | -131 Thousand USD | -10910.687% |
| Bioxytran, Inc. | -4.28 Million USD | -237.009% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -26477.241% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -470.063% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 69.995% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -582.308% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1747.13% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -355.303% |
| Neutra Corp. | -233.46 Thousand USD | -6078.228% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 28.914% |
| PureTech Health plc | -65.69 Million USD | 78.045% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 32.175% |
| IXICO plc | -1.17 Million USD | -1124.448% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -45.301% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 74.751% |
| CSL Limited | 2.64 Billion USD | 100.546% |
| Cellectis S.A. | -103.17 Million USD | 86.02% |